Tiny sensor may spot hidden diabetes risk from common steroids
NCT ID NCT07190378
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 250 adults who are starting steroid treatment for conditions like autoimmune disease or inflammation. Researchers will use a continuous glucose monitor (CGM) for 14 days to see if it can detect early signs of steroid-induced diabetes better than standard tests. The goal is to find out who is at risk and how to manage blood sugar levels during steroid therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
Warsaw, Warsaw, 02-097, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gamifying exercise: could a phone app outperform traditional programs for obesity and diabetes?
- Can your DNA predict how you respond to a diabetes drug?
- Antioxidant-rich diets may fight inflammation in type 2 diabetes — a study investigates
- Can two experimental pills work together safely? a trial seeks answers
- Could meal kits and text messages help curb diabetes in Food-Insecure communities?
- Walking downhill may boost heart health and strength in type 2 diabetes